Publications 2022

Kvassheim M, Revheim MR, Stokke C (2022)
Quantitative SPECT/CT imaging of lead-212: a phantom study
EJNMMI Phys, 9 (1), 52
DOI 10.1186/s40658-022-00481-z, PubMed 35925521

Løndalen A, Blakkisrud J, Revheim ME, Dahle J, Kolstad A, Stokke C (2022)
FDG PET/CT and Dosimetric Studies of ¹⁷⁷Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
Mol Imaging Biol (in press)
DOI 10.1007/s11307-022-01731-3, PubMed 35486292

Müller EG, Edwin TH, Strand BH, Stokke C, Revheim ME, Knapskog AB (2022)
Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?
J Alzheimers Dis, 85 (1), 197-205
DOI 10.3233/JAD-215046, PubMed 34776444

Müller EG, Stokke C, Stokmo HL, Edwin TH, Knapskog AB, Revheim ME (2022)
Evaluation of semi-quantitative measures of ¹⁸F-flutemetamol PET for the clinical diagnosis of Alzheimer's disease
Quant Imaging Med Surg, 12 (1), 493-509
DOI 10.21037/qims-21-188, PubMed 34993096

Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J (2022)
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Eur J Nucl Med Mol Imaging, 49 (6), 1778-1809
DOI 10.1007/s00259-022-05727-7, PubMed 35284969

Stokke C, Kvassheim M, Blakkisrud J (2022)
Radionuclides for Targeted Therapy: Physical Properties
Molecules, 27 (17)
DOI 10.3390/molecules27175429, PubMed 36080198

Stokke C, Nørgaard JN, Feiring Phillips H, Sherwani A, Nuruddin S, Connelly J, Schjesvold F, Revheim ME (2022)
Comparison of [¹⁸F]fluciclovine and [¹⁸F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
Mol Imaging Biol (in press)
DOI 10.1007/s11307-022-01734-0, PubMed 35501622

Publications 2021

Blakkisrud J, Løndalen A, Dahle J, Martinsen AC, Kolstad A, Stokke C (2021)
Myelosuppression in patients treated with ¹⁷⁷Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
Acta Oncol, 60 (11), 1481-1488
DOI 10.1080/0284186X.2021.1959635, PubMed 34425735

Chiesa C, Sjogreen-Gleisner K, Walrand S, Strigari L, Flux G, Gear J, Stokke C, Gabina PM, Bernhardt P, Konijnenberg M (2021)
EANM dosimetry committee series on standard operational procedures: a unified methodology for ^99mTc-MAA pre- and ⁹⁰Y peri-therapy dosimetry in liver radioembolization with ⁹⁰Y microspheres
EJNMMI Phys, 8 (1), 77
DOI 10.1186/s40658-021-00394-3, PubMed 34767102

Degtiarova G, Claus P, Duchenne J, Bogaert J, Nuyts J, Vöros G, Willems R, Larsen CK, Aalen JM, Fjeld JG, Stokke C, Hopp E, Smiseth OA, Voigt JU, Gheysens O (2021)
Left ventricular regional glucose metabolism in combination with septal scar extent identifies CRT responders
Eur J Nucl Med Mol Imaging, 48 (8), 2437-2446
DOI 10.1007/s00259-020-05161-7, PubMed 33416956

Publications 2020

Gear J, Chiesa C, Lassmann M, Gabiña PM, Tran-Gia J, Stokke C, Flux G, EANM Dosimetry Committee (2020)
EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for ¹³¹I mIBG treatment of neuroendocrine tumours
EJNMMI Phys, 7 (1), 15
DOI 10.1186/s40658-020-0282-7, PubMed 32144574

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H (2020)
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524

Larsen CK, Aalen JM, Stokke C, Fjeld JG, Kongsgaard E, Duchenne J, Degtiarova G, Gheysens O, Voigt JU, Smiseth OA, Hopp E (2020)
Regional myocardial work by cardiac magnetic resonance and non-invasive left ventricular pressure: a feasibility study in left bundle branch block
Eur Heart J Cardiovasc Imaging, 21 (2), 143-153
DOI 10.1093/ehjci/jez231, PubMed 31599327

Løndalen A, Blakkisrud J, Revheim ME, Madsbu UE, Dahle J, Kolstad A, Stokke C (2020)
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
Eur J Nucl Med Mol Imaging, 48 (6), 1902-1914
DOI 10.1007/s00259-020-05098-x, PubMed 33196921

Publications 2019

Müller EG, Edwin TH, Stokke C, Navelsaker SS, Babovic A, Bogdanovic N, Knapskog AB, Revheim ME (2019)
Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic
PLoS One, 14 (8), e0221365
DOI 10.1371/journal.pone.0221365, PubMed 31430334

Walrand S, Chiesa C, Gabina PM, Chouin N, Gear J, Stokke C, Bernhardt P, Gleisner KS, Strigari L, Konijnenberg M, EANM Dosimetry Committee (2019)
Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma
J Vasc Interv Radiol, 30 (12), 2047-2048
DOI 10.1016/j.jvir.2019.08.030, PubMed 31676203

Publications 2018

Halsne T, Müller EG, Spiten AE, Sherwani AG, Gyland Mikalsen LT, Revheim ME, Stokke C (2018)
The Effect of New Formulas for Lean Body Mass on Lean-Body-Mass-Normalized SUV in Oncologic ¹⁸F-FDG PET/CT
J Nucl Med Technol, 46 (3), 253-259
DOI 10.2967/jnmt.117.204586, PubMed 29599401

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A (2018)
Pre-dosing with lilotomab prior to therapy with ¹⁷⁷Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
DOI 10.1007/s00259-018-3964-9, PubMed 29470615

Publications 2017

Ausland L, Revheim ME, Skretting A, Stokke C (2017)
Respiratory motion during ⁹⁰Yttrium PET contributes to underestimation of tumor dose and overestimation of normal liver tissue dose
Acta Radiol, 59 (2), 132-139
DOI 10.1177/0284185117710052, PubMed 28509566

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C (2017)
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate ¹⁷⁷Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035

Mikalsen LTG, Arnesen MR, Bogsrud TV, Dale E, Stokke C (2017)
Combining radioiodine and external beam radiation therapy: the potential of integrated treatment planning for differentiated thyroid cancer
Acta Oncol, 56 (6), 894-897
DOI 10.1080/0284186X.2017.1286384, PubMed 28464741

Sjögreen Gleisner K, Spezi E, Solny P, Gabina PM, Cicone F, Stokke C, Chiesa C, Paphiti M, Brans B, Sandström M, Tipping J, Konijnenberg M, Flux G (2017)
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey
EJNMMI Phys, 4 (1), 28
DOI 10.1186/s40658-017-0193-4, PubMed 29199391

Stokke C, Gabiña PM, Solný P, Cicone F, Sandström M, Gleisner KS, Chiesa C, Spezi E, Paphiti M, Konijnenberg M, Aldridge M, Tipping J, Wissmeyer M, Brans B, Bacher K, Kobe C, Flux G (2017)
Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
EJNMMI Phys, 4 (1), 27
DOI 10.1186/s40658-017-0194-3, PubMed 29164483

Publications 2016

Arnesen MR, Rekstad BL, Stokke C, Bruheim K, Løndalen AM, Hellebust TP, Malinen E (2016)
Short-course PET based simultaneous integrated boost for locally advanced cervical cancer
Radiat Oncol, 11, 39
DOI 10.1186/s13014-016-0612-z, PubMed 26968827

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C (2016)
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
J Nucl Med, 58 (1), 55-61
DOI 10.2967/jnumed.116.180471, PubMed 27587710

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C (2016)
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270

Publications 2015

Dale Rein I, Stokke C, Jalal M, Myklebust JH, Patzke S, Stokke T (2015)
New distinct compartments in the G2 phase of the cell cycle defined by the levels of γH2AX
Cell Cycle, 14 (20), 3261-9
DOI 10.1080/15384101.2015.1087617, PubMed 26317799

Publications 2014

Fossum-Raunehaug S, Helgesen E, Stokke C, Skarstad K (2014)
Escherichia coli SeqA structures relocalize abruptly upon termination of origin sequestration during multifork DNA replication
PLoS One, 9 (10), e110575
DOI 10.1371/journal.pone.0110575, PubMed 25333813

Gulliksrud K, Stokke C, Martinsen AC (2014)
How to measure CT image quality: variations in CT-numbers, uniformity and low contrast resolution for a CT quality assurance phantom
Phys Med, 30 (4), 521-6
DOI 10.1016/j.ejmp.2014.01.006, PubMed 24530005

Publications 2012

Stokke C, Flåtten I, Skarstad K (2012)
An easy-to-use simulation program demonstrates variations in bacterial cell cycle parameters depending on medium and temperature
PLoS One, 7 (2), e30981
DOI 10.1371/journal.pone.0030981, PubMed 22348034

Publications 2011

Landsverk KS, Patzke S, Rein ID, Stokke C, Lyng H, De Angelis PM, Stokke T (2011)
Three independent mechanisms for arrest in G2 after ionizing radiation
Cell Cycle, 10 (5), 819-29
DOI 10.4161/cc.10.5.14968, PubMed 21325885

Publications 2010

Stokke C, Waldminghaus T, Skarstad K (2010)
Replication patterns and organization of replication forks in Vibrio cholerae
Microbiology (Reading), 157 (Pt 3), 695-708
DOI 10.1099/mic.0.045112-0, PubMed 21163839